Pharmaceutical companies promise to allocate 200 million doses of vaccine to poor countries

Wednesday, Sanofi and GSK laboratories promised to allocate 200 million doses of the vaccine to the international COVAX program, which was launched by the World Health Organization with the aim of contributing to ensuring a fair distribution of the next vaccines against Covid-19.

The French company Sanofi and British GSK stated that they had signed a declaration of intent with GAVI, the Global Alliance for Vaccines and Immunization, which supervises the global Covax program.

The statement added that the two companies "intend to put 200 million doses of their vaccine (...) at the disposal of the program, if approved by the regular authorities and on the condition that contracts are signed."

In September, Sanofi and the GSA began clinical tests on humans for their vaccine with the participation of 440 people, and they expect to obtain the first results "in early December 2020, provided that a pivotal trial of the third phase can be launched before the end of the year."

The two companies explained, "If the data of these experiences show sufficient evidence to submit a license application, it is expected that the application for approval of the regulations will be raised in the first half of 2021."

The Executive Vice President of Sanofi Pasteur said, "The pledge that we make today gives us collectively the best opportunities to control the pandemic," according to what the statement quoted, stressing "the determination to ensure that our vaccines against Covid-19 will be affordable and available to the most vulnerable population of all ages around the world.”

Roger Connor, President of GSK Vaccines, said, "Since we began developing vaccines against Covid-19, GSK has committed to making it available to everyone around the world."